<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.2.335">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>talks - Sarcopenia in Colorectal Cancer</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1.6em;
  vertical-align: middle;
}
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>


<script src="site_libs/quarto-nav/quarto-nav.js"></script>
<script src="site_libs/quarto-nav/headroom.min.js"></script>
<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="site_libs/quarto-search/fuse.min.js"></script>
<script src="site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="./">
<script src="site_libs/quarto-html/quarto.js"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="site_libs/quarto-html/anchor.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="site_libs/bootstrap/bootstrap.min.js"></script>
<link href="site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="site_libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">
<script id="quarto-search-options" type="application/json">{
  "location": "navbar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "end",
  "type": "overlay",
  "limit": 20,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit"
  }
}</script>


<link rel="stylesheet" href="styles.css">
</head>

<body class="nav-fixed">

<div id="quarto-search-results"></div>
  <header id="quarto-header" class="headroom fixed-top">
    <nav class="navbar navbar-expand-lg navbar-dark ">
      <div class="navbar-container container-fluid">
      <div class="navbar-brand-container">
    <a class="navbar-brand" href="./index.html">
    <span class="navbar-title">talks</span>
    </a>
  </div>
          <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarCollapse" aria-controls="navbarCollapse" aria-expanded="false" aria-label="Toggle navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">
  <span class="navbar-toggler-icon"></span>
</button>
          <div class="collapse navbar-collapse" id="navbarCollapse">
            <ul class="navbar-nav navbar-nav-scroll me-auto">
  <li class="nav-item">
    <a class="nav-link" href="./index.html">
 <span class="menu-text">Home</span></a>
  </li>  
  <li class="dropdown-header">
 <span class="menu-text">about.qmd</span></li>
</ul>
              <div id="quarto-search" class="" title="Search"></div>
          </div> <!-- /navcollapse -->
      </div> <!-- /container-fluid -->
    </nav>
</header>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article page-navbar">
<!-- sidebar -->
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">On this page</h2>
   
  <ul>
  <li><a href="#colorectal-cancer" id="toc-colorectal-cancer" class="nav-link active" data-scroll-target="#colorectal-cancer">Colorectal Cancer</a>
  <ul class="collapse">
  <li><a href="#surgical-patients" id="toc-surgical-patients" class="nav-link" data-scroll-target="#surgical-patients">Surgical Patients</a></li>
  <li><a href="#colectomy-for-colorectal-cancer" id="toc-colectomy-for-colorectal-cancer" class="nav-link" data-scroll-target="#colectomy-for-colorectal-cancer">Colectomy for colorectal cancer</a></li>
  <li><a href="#colorectal-cancer-1" id="toc-colorectal-cancer-1" class="nav-link" data-scroll-target="#colorectal-cancer-1">Colorectal Cancer</a>
  <ul class="collapse">
  <li><a href="#sarcopenia-and-advanced-crc" id="toc-sarcopenia-and-advanced-crc" class="nav-link" data-scroll-target="#sarcopenia-and-advanced-crc">Sarcopenia and advanced CRC</a></li>
  </ul></li>
  <li><a href="#sarcopenia-and-inflammatory-bowel-disease" id="toc-sarcopenia-and-inflammatory-bowel-disease" class="nav-link" data-scroll-target="#sarcopenia-and-inflammatory-bowel-disease">Sarcopenia and inflammatory bowel disease</a>
  <ul class="collapse">
  <li><a href="#inflammation-in-colorectal-cancer" id="toc-inflammation-in-colorectal-cancer" class="nav-link" data-scroll-target="#inflammation-in-colorectal-cancer">Inflammation in Colorectal Cancer</a></li>
  </ul></li>
  </ul></li>
  </ul>
</nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title">Sarcopenia in Colorectal Cancer</h1>
</div>



<div class="quarto-title-meta">

    
  
    
  </div>
  

</header>

<section id="colorectal-cancer" class="level1">
<h1>Colorectal Cancer</h1>
<section id="surgical-patients" class="level2">
<h2 class="anchored" data-anchor-id="surgical-patients">Surgical Patients</h2>
<p>2100 patients with LOS for 1139.predictors of LOS: age, surgical approach, major complications (incidence rate ratio [IRR] 2.42; 95% confidence interval [CI] 2.18–2.68), study cohort, and three body composition profiles characterized by myosteatosis combined with either sarcopenia (IRR, 1.27; 95% CI 1.12–1.43) or VO (IRR, 1.25; 95% CI 1.10–1.42), and myosteatosis combined with both sarcopenia and VO (IRR, 1.58; 95% CI 1.29–1.93). risk of readmission was associated with VO alone (odds ratio [OR] 2.66; 95% CI 1.18–6.00); P = 0.018), VO combined with myosteatosis (OR, 2.72; 95% CI 1.36–5.46; P = 0.005), or VO combined with myosteatosis and sarcopenia (OR, 2.98; 95% CI 1.06–5.46; P = 0.038). Importantly, the effect of body composition profiles on LOS and readmission was independent of major complications” <span class="citation" data-cites="martin2669">(<a href="#ref-martin2669" role="doc-biblioref">Martin et al. 2018</a>)</span></p>
<p>Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 2012;107(6):931–6<span class="citation" data-cites="lieffers931">(<a href="#ref-lieffers931" role="doc-biblioref">J. R. Lieffers et al. 2012</a>)</span></p>
<p>142 colectomy patients, of whom 17 had sarcopenia showed sarcopenia predicted complications after colectomy<span class="citation" data-cites="huangO256">(<a href="#ref-huangO256" role="doc-biblioref"><strong>huangO256?</strong></a>)</span>. However, addition of grip strength and low gait speed added to ability to predict postoperative complications.</p>
<p>Psoas muscle area associated with postop complications after colectomy <span class="citation" data-cites="jonesO20">(<a href="#ref-jonesO20" role="doc-biblioref">Jones et al. 2015</a>)</span></p>
<p>124 laparoscopic colectomies. No difference in LOS, complications, or functional recovery (time to first flatus, oral diet tolerance and mobilization) depending upon sarcopenia.<span class="citation" data-cites="pedziwiatr779">(<a href="#ref-pedziwiatr779" role="doc-biblioref"><strong>pedziwiatr779?</strong></a>)</span></p>
<p>60 patients who underwent laparoscopic colorectal resection for primary colorectal cancer sarcopenia group (normalized total psoas muscle area in males, &lt;538 mm/m(2); in females, &lt;346 mm/m(2); n = 20) and nonsarcopenia group (n = 40). No significant differences in the overall rate of postoperative complications (20% vs.&nbsp;20%) or major postoperative complications of Clavien-Dindo Grade III or more (5% vs.&nbsp;5%) were observed <span class="citation" data-cites="ouchi366">(<a href="#ref-ouchi366" role="doc-biblioref"><strong>ouchi366?</strong></a>)</span></p>
<p>Muscle radiodensity and mortality in patients with colorectal cancer Kroenke 3008 pmid 29797673</p>
</section>
<section id="colectomy-for-colorectal-cancer" class="level2">
<h2 class="anchored" data-anchor-id="colectomy-for-colorectal-cancer">Colectomy for colorectal cancer</h2>
<p>Impact of sarcopenia on surgical and oncologic outcomes of laparoscopic surgery for colorectal cancer. Sarcopenia associated with readmission after colectomy for colorectal cancer 209 patients who underwent laparoscopic surgery for colorectal cancer. sarcopenia was 41.1%. Sarcopenic patients experienced shorter operative times and a lower incidence of surgical site infections; however, the incidence of severe postoperative complications and readmission were increased for this group. Although the 3-year disease-free survival rate was not statistically different between groups, sarcopenic patients had a significantly worse 3-year overall survival rate compared with than the non-sarcopenic group.<span class="citation" data-cites="takenami2686">(<a href="#ref-takenami2686" role="doc-biblioref"><strong>takenami2686?</strong></a>)</span></p>
</section>
<section id="colorectal-cancer-1" class="level2">
<h2 class="anchored" data-anchor-id="colorectal-cancer-1">Colorectal Cancer</h2>
<p>Data from Kaiser <span class="citation" data-cites="xiao615">(<a href="#ref-xiao615" role="doc-biblioref">Xiao et al. 2019</a>)</span> examined 3263 patients with non-metastatic colorectal cancer. Black patients had higher lower rates of sarcopenia according to the definition of Prado et al.&nbsp;Patients with higher neutrophil-lymphocyte ratio had higher risk of muscle abnormality. CT scan at L3 was analyed to determine SMI,IMAT,VAT,SAT and TAT (=VAT+SAT+IMAT) using SliceOMatic. Threshold values determined for optimal stratification (cf {<span class="citation" data-cites="martin1539">Martin et al. (<a href="#ref-martin1539" role="doc-biblioref">2013</a>)</span>;<span class="citation" data-cites="prado639">(<a href="#ref-prado639" role="doc-biblioref"><strong>prado639?</strong></a>)</span>})</p>
<p>Kaiser 3262 patients with stage I-III colorectal cancer of whom 42% were sarcopenic. <span class="citation" data-cites="caan1008">(<a href="#ref-caan1008" role="doc-biblioref">Caan et al. 2017</a>)</span> examined body composition and survival from colorecal cncer at Kaiser. Worst survival with low muscle mass and high adiposity. Slightly worse survival with elevated VAT but no worse survival with increases SAT. Different relationships between TAT and survival by sex.</p>
<blockquote class="blockquote">
<p>The existence of nonlinear relationships between sarcopenia and body composition measures and overall mortality were assessed by the addition of restricted cubic splines and use of the likelihood ratio test that compared models with the linear terms only with those with both linear and cubic spline terms. Effect modification was assessed using cross-product terms for body composition measures and the following covariates: sex, age at diagnosis (&lt;60, 60–&lt;70, and 70 years), BMI category (18.5&lt;25, 25–&lt;30, and 30 kg/m2), weight change prior to diagnosis (stable, 5% loss, 5% gain), cancer stage (I, II/III), tumor site (rectal vs.&nbsp;colon), and chemotherapy (any vs.&nbsp;none).</p>
</blockquote>
<p>Trejo-Avila M, Bozada-Gutiérrez K, Valenzuela-Salazar C, Herrera-Esquivel J, Moreno-Portillo M. Sarcopenia predicts worse postoperative outcomes and decreased survival rates in patients with colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2021;36(6):1077–96. doi:&nbsp;10.1007/s00384-021-03839-4</p>
<p>.Preoperative Assessment of Cancer in the Elderly (PACE): Audisio RA, Pope D, Ramesh HS, Gennari R, van Leeuwen BL, West C, et al.&nbsp;Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol. 2008;65:156–63</p>
<p>Heriot AG, Tekkis PP, Smith JJ, Cohen CR, Montgomery A, Audisio RA, et al.&nbsp;Prediction of postoperative mortality in elderly patients with colorectal cancer. Dis Colon Rectum. 2006;49:816–24</p>
<p>Pope D, Ramesh H, Gennari R, Corsini G, Maffezzini M, Hoekstra HJ, et al.&nbsp;Pre-operative assessment of cancer in the elderly (PACE): a comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery. Surg Oncol. 2006;15:189–97</p>
<section id="sarcopenia-and-advanced-crc" class="level3">
<h3 class="anchored" data-anchor-id="sarcopenia-and-advanced-crc">Sarcopenia and advanced CRC</h3>
<p>French investigators studied 51 patients with mCRC and found sarcopenia in 70% (39% of women and 82% of men). In multivariate analysis including age, sex, BMI, sarcopenia, SAT, and VAT, the only factor associated with Grade 3-4 toxicities was sarcopenia (odds ratio = 13.55; 95% confidence interval [1.08; 169.31], P = 0.043).{<span class="citation" data-cites="barrett_Nutritionand">(<a href="#ref-barrett_Nutritionand" role="doc-biblioref"><strong>barrett_Nutritionand?</strong></a>)</span> Cancer v6 2014(4)}</p>
<p>Data from Kaiser <span class="citation" data-cites="xiao615">(<a href="#ref-xiao615" role="doc-biblioref">Xiao et al. 2019</a>)</span> examined 3263 patients with non-metastatic colorectal cancer. Black patients had higher lower rates of sarcopenia according to the definition of Prado et al.&nbsp;Patients with higher neutrophil-lymphocyte ratio had higher risk of muscle abnormality. CT scan at L3 was analyed to determine SMI,IMAT,VAT,SAT and TAT (=VAT+SAT+IMAT) using SliceOMatic. Threshold values determined for optimal stratification (cf {<span class="citation" data-cites="martin1539">Martin et al. (<a href="#ref-martin1539" role="doc-biblioref">2013</a>)</span>;<span class="citation" data-cites="prado639">(<a href="#ref-prado639" role="doc-biblioref"><strong>prado639?</strong></a>)</span>})</p>
<p>Low muscle mass has been shown to be associated with poor prognosis cancer patients.<span class="citation" data-cites="martin1539">(<a href="#ref-martin1539" role="doc-biblioref">Martin et al. 2013</a>)</span> This may be due to overal frailty or low muscle mass may lead to increased toxicity from chemotherapy due to pharmacokinetic mechanism. 5-FU is hydrophilic and it volume of distribution includes the muscle compartment, while oxaliplatin is hydrophobic, with distribution in the fat compartment<span class="citation" data-cites="bozzetti2107">(<a href="#ref-bozzetti2107" role="doc-biblioref">Bozzetti 2017</a>)</span>.</p>
<p>In addition, loss of muscle mass during chemotherapy for advanced cancers is a poor prognosticator.</p>
<p>Blauhoff <span class="citation" data-cites="blauwhoff-buskermolen1339">(<a href="#ref-blauwhoff-buskermolen1339" role="doc-biblioref">Blauwhoff-Buskermolen et al. 2016</a>)</span> studis 67 patients with metastatic colorectal cancer. Muscle area on CT decreased by 6.1% over 3 months. Patients in the lowest tertile (loss of 9%) had worse survial. Overall survival 17.5 months for first-line chemotherapy and 8.5months for second-line. Baseline muscle density was predictive of survival on multivariable analysis, but low SMI at baseline was not associatesd with survival. (This may be because sarcopenic obesity is the major risk factor, and there were few obese patients in the study cohort) &gt;Muscle loss of 9% or more remained independently associated with survival when adjusted for sex, age, baseline lactate dehydrogenase concentration, comorbidity, mono-organ or multiorgan metastases, treatment line, and tumor progression at first evaluation by computed tomography scan (hazard ratio, 4.47; 95% CI, 2.21 to 9.05; P , .001). We found a mean coefficient of variation between observers of 0.6% for skeletal muscle area in a random sample of 20 patients, which is regarded to be low.<span class="citation" data-cites="macdonald342">(<a href="#ref-macdonald342" role="doc-biblioref">MacDonald, Greig, and Baracos 2011</a>)</span>. Changes between the first and second scans were calculated as a rate of change per 3 months, meaning change per first evaluation, to compare with available literature.[awad74][prado1583]Relative muscle change per 3 months was categorized into tertiles of muscle change: tertile one, highest muscle loss up to 9%; tertile two, muscle loss of 9% to 1.5%; and tertile three, muscle loss of 1.5% until highest gain in muscle. However, the survival curve of tertile two was not significantly different from the survival curve of tertile three (log-rank P = .961); therefore tertiles two and three were pooled (cutoff, 9% muscle loss).</p>
<p>Kurk <span class="citation" data-cites="kurk1033">(<a href="#ref-kurk1033" role="doc-biblioref">Kurk et al. 2020</a>)</span> found that skeletal muscle loss during chemotherapy was associated with decreased progression-free and overall- survival in metastatic colorectal cancer.</p>
<blockquote class="blockquote">
<p>Detailed changes in skeletal muscle mass and body weight during CAIRO3 treatments were previously reported.KurkS, p909, 2018) We additionally analyzed changes in SMI and BMI during these treatments by linear mixed effects models.(Bayar MA,p311,2017) The baseline value of the outcome (SMI/BMI) was included in the outcome vector. Potential confounders were age, sex, lactate dehydrogenase (LDH) levels, best response to initial six cycles CAPOX‐B, resection of the primary tumor, and the number of metastatic sites. The final model was selected based on the Akaike Information Criterion (AIC) and included: treatment arm, time, age, sex, resection primary tumor, and the interaction of treatment arm by time as fixed effects. Modeling time as a random effect did not increase the model fit as indicated by the AIC. To investigate differences in SMI and BMI changes over time between the CAIRO3 treatment arms, we checked the significance of the two‐way interaction including treatment arm by time.</p>
</blockquote>
<blockquote class="blockquote">
<p>During p2 (maintenance CAP‐B/observation), again absolute SMI and BMI at the start (t1) of treatment were not associated with early progression and death. In contrast, SMI loss and BMI loss during treatment were associated with early progression and death.</p>
</blockquote>
<p>Fogelman <span class="citation" data-cites="fogelman307">(<a href="#ref-fogelman307" role="doc-biblioref">Fogelman et al. 2014</a>)</span> treated patients undergoing chemotherapy with a novel agent designed to reduce muscle less. CT scans at 2 months were compared with baseline scans prior to chemotherapy.</p>
<blockquote class="blockquote">
<p>Changes in skeletal muscle were determined using routinely acquired CT scans for patients on the study. We calculated skeletal muscle cross-sectional area (cm2) at the third lumbar vertebra (L3). A single slice at the mid-point of L3 was used, preferably a 2.5-mm slice if available, and a 5-mm slice if a 2.5-mm slice was not available. The L3 is a landmark that has been extensively used and validated in studies assessing body composition in cancer patients [<span class="citation" data-cites="shen2333">Shen et al. (<a href="#ref-shen2333" role="doc-biblioref">2004</a>)</span>]<span class="citation" data-cites="prado269">(<a href="#ref-prado269" role="doc-biblioref">C. M. M. Prado, Birdsell, and Baracos 2009</a>)</span> . Skeletal muscle surface areas were determined using Slice-o-Matic softwareTM, version 4.3 (Tomovision, Montreal, QC, Canada) using pre-established thresholds of Hounsfield units (HU) of −29 to +150 <span class="citation" data-cites="mitsiopoulos115">(<a href="#ref-mitsiopoulos115" role="doc-biblioref">Mitsiopoulos et al. 1998</a>)</span>. We additionally evaluated adipose tissue cross-sectional area (subcutaneous, visceral, and intramuscular) in the L3 region as described previously <span class="citation" data-cites="mourtzakis997">(<a href="#ref-mourtzakis997" role="doc-biblioref">Mourtzakis et al. 2008</a>)</span>. Changes in muscle and adipose tissue surface areas over time were determined for each patient from the baseline study to the first CT post treatment, done after 2 months. We looked at muscle loss as a continuous variable and defined “meaningful loss” as greater than a 6 cm2 difference from the baseline to the second scan. We chose this cut point as it is equivalent to 1 kg of skeletal muscle and is associated with physical function (i.e., muscle strength). Additionally, this cut point has been used to investigate significant changes in muscle mass throughout cancer disease trajectory [<span class="citation" data-cites="shen2333">Shen et al. (<a href="#ref-shen2333" role="doc-biblioref">2004</a>)</span>]<span class="citation" data-cites="frontera1038">(<a href="#ref-frontera1038" role="doc-biblioref">Frontera et al. 1988</a>)</span><span class="citation" data-cites="prado1012">(<a href="#ref-prado1012" role="doc-biblioref">C. M. Prado et al. 2013</a>)</span>.</p>
</blockquote>
<p>Prado <span class="citation" data-cites="prado1012">(<a href="#ref-prado1012" role="doc-biblioref">C. M. Prado et al. 2013</a>)</span> looked at changes in 1279 CT scans in 368 patients with advanced cancer. The last available interval with CT scans was chosen for comparison. Categorized into stable, gaining, losing for muscle and for adipose tissue. Adipose tissue was ?? sum of visceral adipose tissue and subcutaneous tissue. (<strong>Did not use SMI</strong>). Muscel loss and adipose loss seemed correlated, with larger magnitude of adipose tissue loss at short interval to death. (Authors conclusion that muscle and adipose tissue loss in the past 3 months of life is likely not possible) &gt;Advanced-cancer patients (n = 368; median survival: 196 d) had a total of 1279 CT images over the course of their disease. With consideration of all time points, muscle loss occurred in 39% of intervals between any 2 scans. However, the overall frequency of muscle gain was 15.4%, and muscle was stable in 45.6% of intervals between any 2 scans, which made the maintenance or gain of muscle the predominant behavior. Multinomial logistic regression revealed that being within 90 d (compared with &gt;90 d) from death was the principal risk factor for muscle loss (OR: 2.67; 95% CI: 1.45, 4.94; P = 0.002), and muscle gain was correspondingly less likely (OR: 0.37; 95% CI: 0.20, 0.69; P = 0.002) at this time. Sex, age, BMI, and tumor group were not significant predictors of muscle loss or gain. A much higher proportion of men (61%) than women (31%) met the criteria for sarcopenia. Changes in muscle and adipose tissue over time were calculated as the absolute loss or gain of tissue area during each scan interval. The precision error of measurements was ~1.5% <span class="citation" data-cites="mourtzakis997">(<a href="#ref-mourtzakis997" role="doc-biblioref">Mourtzakis et al. 2008</a>)</span> with a minimum detectable change of ~3 cm2. We attributed the change during each interval into the following categories: 1) muscle loss ≥6.0 cm2, 2) stable muscle ±5.9 cm2, or 3) muscle gain ≥6.0cm2. These cutoffs are equivalent to a loss or gain of ≥1 kg of skeletal muscle on a whole-body basis and are associated with alterations in muscle strength [<span class="citation" data-cites="shen2333">Shen et al. (<a href="#ref-shen2333" role="doc-biblioref">2004</a>)</span>]<span class="citation" data-cites="frontera1038">(<a href="#ref-frontera1038" role="doc-biblioref">Frontera et al. 1988</a>)</span>. For adipose tissue, categories were based on the equivalence of 14.7 cm2 total fat at L3 and 1 kg tissue on a whole-body basis <span class="citation" data-cites="shen2333">(<a href="#ref-shen2333" role="doc-biblioref">Shen et al. 2004</a>)</span>; therefore, changes during each interval were categorized as 1) adipose tissue loss ≥14.7 cm2, 2) stable adipose tissue ±14.6 cm2, or 3) adipose tissue gain ≥14.7 cm2. CT scans were taken for the diagnosis, confirmation of stage, and follow-up of disease progression and treatment. With the understanding that cachexia evolves markedly in the end of life and to take advantage of repeated measures, we focused on patients with ≥2 CT images (2–6 images) on record during the year preceding their deaths (n = 368). A selection bias was not apparent in this sample; we showed that the sex distribution, age at death, survival time, primary tumor site, tumor morphology, and body-composition features (ie, muscle and adipose tissues) in patients who had only a single scan were not different from those of the overall cohort at an equal time to death (P &gt; 0.1). Patients included in the analysis (n = 368) were of advanced stage, and the median time to death of all groups was &lt;1 y.</p>
<p>Lieffers and advanced colorectal cancer: Found liver and spleen increased in size in terminal patients (causing increase in basal metabolic rate). Found more rapid muscle loss with progressive disease <span class="citation" data-cites="lieffers1173">(<a href="#ref-lieffers1173" role="doc-biblioref">Jessica R. Lieffers et al. 2009</a>)</span>. Different thresholds for VAT (-150 to -50) and SAT(-190 to -30). Also estimated muscel surface area using measurements 5cm above L4<span class="citation" data-cites="shen2333">(<a href="#ref-shen2333" role="doc-biblioref">Shen et al. 2004</a>)</span>. Most rapid change in body composition between 4 months and 1 month prior to death. &gt;14% of patients gained skeletal muscle during the year preceding death from colorectal cancer (+4.7 ± 5.4%/100 d).</p>
</section>
</section>
<section id="sarcopenia-and-inflammatory-bowel-disease" class="level2">
<h2 class="anchored" data-anchor-id="sarcopenia-and-inflammatory-bowel-disease">Sarcopenia and inflammatory bowel disease</h2>
<section id="inflammation-in-colorectal-cancer" class="level3">
<h3 class="anchored" data-anchor-id="inflammation-in-colorectal-cancer">Inflammation in Colorectal Cancer</h3>
<p>{<span class="citation" data-cites="feliciano">(<a href="#ref-feliciano" role="doc-biblioref"><strong>feliciano?</strong></a>)</span> e172319} PMID 28796857PMID 24122750PMID 24866483</p>



</section>
</section>
</section>

<div id="quarto-appendix" class="default"><section class="quarto-appendix-contents" role="doc-bibliography"><h2 class="anchored quarto-appendix-heading">References</h2><div id="refs" class="references csl-bib-body hanging-indent" role="doc-bibliography">
<div id="ref-blauwhoff-buskermolen1339" class="csl-entry" role="doc-biblioentry">
Blauwhoff-Buskermolen, Susanne, Kathelijn S. Versteeg, Marian A. E. de van der Schueren, Nicole R. den Braver, Johannes Berkhof, Jacqueline A. E. Langius, and Henk M. W. Verheul. 2016. <span>“Loss of <span>Muscle Mass During Chemotherapy Is Predictive</span> for <span>Poor Survival</span> of <span>Patients With Metastatic Colorectal Cancer</span>.”</span> <em>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology</em> 34 (12): 1339–44. <a href="https://doi.org/10.1200/JCO.2015.63.6043">https://doi.org/10.1200/JCO.2015.63.6043</a>.
</div>
<div id="ref-bozzetti2107" class="csl-entry" role="doc-biblioentry">
Bozzetti, F. 2017. <span>“Forcing the Vicious Circle: Sarcopenia Increases Toxicity, Decreases Response to Chemotherapy and Worsens with Chemotherapy.”</span> <em>Annals of Oncology: Official Journal of the European Society for Medical Oncology</em> 28 (9): 2107–18. <a href="https://doi.org/10.1093/annonc/mdx271">https://doi.org/10.1093/annonc/mdx271</a>.
</div>
<div id="ref-caan1008" class="csl-entry" role="doc-biblioentry">
Caan, Bette J., Jeffrey A. Meyerhardt, Candyce H. Kroenke, Stacey Alexeeff, Jingjie Xiao, Erin Weltzien, Elizabeth Cespedes Feliciano, et al. 2017. <span>“Explaining the <span>Obesity Paradox</span>: <span>The Association</span> Between <span>Body Composition</span> and <span>Colorectal Cancer Survival</span> (<span>C-SCANS Study</span>).”</span> <em>Cancer Epidemiology, Biomarkers &amp; Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology</em> 26 (7): 1008–15. <a href="https://doi.org/10.1158/1055-9965.EPI-17-0200">https://doi.org/10.1158/1055-9965.EPI-17-0200</a>.
</div>
<div id="ref-fogelman307" class="csl-entry" role="doc-biblioentry">
Fogelman, David R., Holly Holmes, Khalil Mohammed, Matthew H. G. Katz, Carla M. Prado, Jessica Lieffers, Naveen Garg, et al. 2014. <span>“Does <span>IGFR1</span> Inhibition Result in Increased Muscle Mass Loss in Patients Undergoing Treatment for Pancreatic Cancer?”</span> <em>Journal of Cachexia, Sarcopenia and Muscle</em> 5 (4): 307–13. <a href="https://doi.org/10.1007/s13539-014-0145-y">https://doi.org/10.1007/s13539-014-0145-y</a>.
</div>
<div id="ref-frontera1038" class="csl-entry" role="doc-biblioentry">
Frontera, W. R., C. N. Meredith, K. P. O’Reilly, H. G. Knuttgen, and W. J. Evans. 1988. <span>“Strength Conditioning in Older Men: Skeletal Muscle Hypertrophy and Improved Function.”</span> <em>Journal of Applied Physiology (Bethesda, Md.: 1985)</em> 64 (3): 1038–44. <a href="https://doi.org/10.1152/jappl.1988.64.3.1038">https://doi.org/10.1152/jappl.1988.64.3.1038</a>.
</div>
<div id="ref-jonesO20" class="csl-entry" role="doc-biblioentry">
Jones, K. I., B. Doleman, S. Scott, J. N. Lund, and J. P. Williams. 2015. <span>“Simple Psoas Cross-Sectional Area Measurement Is a Quick and Easy Method to Assess Sarcopenia and Predicts Major Surgical Complications.”</span> Journal {{Article}}. <em>Colorectal Dis</em> 17 (1): O20–6. <a href="https://doi.org/10.1111/codi.12805">https://doi.org/10.1111/codi.12805</a>.
</div>
<div id="ref-kurk1033" class="csl-entry" role="doc-biblioentry">
Kurk, Sophie A., Petra H. M. Peeters, Bram Dorresteijn, Pim A. de Jong, Marion Jourdan, Geert-Jan M. Creemers, Frans L. G. Erdkamp, et al. 2020. <span>“Loss of Skeletal Muscle Index and Survival in Patients with Metastatic Colorectal Cancer: <span>Secondary</span> Analysis of the Phase 3 <span>CAIRO3</span> Trial.”</span> <em>Cancer Medicine</em> 9 (3): 1033–43. <a href="https://doi.org/10.1002/cam4.2787">https://doi.org/10.1002/cam4.2787</a>.
</div>
<div id="ref-lieffers931" class="csl-entry" role="doc-biblioentry">
Lieffers, J. R., O. F. Bathe, K. Fassbender, M. Winget, and V. E. Baracos. 2012. <span>“Sarcopenia Is Associated with Postoperative Infection and Delayed Recovery from Colorectal Cancer Resection Surgery.”</span> <em>British Journal of Cancer</em> 107 (6): 931–36. <a href="https://doi.org/10.1038/bjc.2012.350">https://doi.org/10.1038/bjc.2012.350</a>.
</div>
<div id="ref-lieffers1173" class="csl-entry" role="doc-biblioentry">
Lieffers, Jessica R., Marina Mourtzakis, Kevin D. Hall, Linda J. McCargar, Carla M. M. Prado, and Vickie E. Baracos. 2009. <span>“A Viscerally Driven Cachexia Syndrome in Patients with Advanced Colorectal Cancer: Contributions of Organ and Tumor Mass to Whole-Body Energy Demands.”</span> <em>The American Journal of Clinical Nutrition</em> 89 (4): 1173–79. <a href="https://doi.org/10.3945/ajcn.2008.27273">https://doi.org/10.3945/ajcn.2008.27273</a>.
</div>
<div id="ref-macdonald342" class="csl-entry" role="doc-biblioentry">
MacDonald, Alisdair J., Carolyn A. Greig, and Vickie Baracos. 2011. <span>“The Advantages and Limitations of Cross-Sectional Body Composition Analysis.”</span> <em>Current Opinion in Supportive and Palliative Care</em> 5 (4): 342–49. <a href="https://doi.org/10.1097/SPC.0b013e32834c49eb">https://doi.org/10.1097/SPC.0b013e32834c49eb</a>.
</div>
<div id="ref-martin1539" class="csl-entry" role="doc-biblioentry">
Martin, Lisa, Laura Birdsell, Neil Macdonald, Tony Reiman, M. Thomas Clandinin, Linda J. McCargar, Rachel Murphy, Sunita Ghosh, Michael B. Sawyer, and Vickie E. Baracos. 2013. <span>“Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index.”</span> <em>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology</em> 31 (12): 1539–47. <a href="https://doi.org/10.1200/JCO.2012.45.2722">https://doi.org/10.1200/JCO.2012.45.2722</a>.
</div>
<div id="ref-martin2669" class="csl-entry" role="doc-biblioentry">
Martin, Lisa, Jessica Hopkins, Georgios Malietzis, J. T. Jenkins, Michael B. Sawyer, Ron Brisebois, Anthony MacLean, Gregg Nelson, Leah Gramlich, and Vickie E. Baracos. 2018. <span>“Assessment of <span>Computed Tomography</span> (<span>CT</span>)-<span>Defined Muscle</span> and <span>Adipose Tissue Features</span> in <span>Relation</span> to <span>Short-Term Outcomes After Elective Surgery</span> for <span>Colorectal Cancer</span>: <span>A Multicenter Approach</span>.”</span> <em>Annals of Surgical Oncology</em> 25 (9): 2669–80. <a href="https://doi.org/10.1245/s10434-018-6652-x">https://doi.org/10.1245/s10434-018-6652-x</a>.
</div>
<div id="ref-mitsiopoulos115" class="csl-entry" role="doc-biblioentry">
Mitsiopoulos, N., R. N. Baumgartner, S. B. Heymsfield, W. Lyons, D. Gallagher, and R. Ross. 1998. <span>“Cadaver Validation of Skeletal Muscle Measurement by Magnetic Resonance Imaging and Computerized Tomography.”</span> <em>Journal of Applied Physiology (Bethesda, Md.: 1985)</em> 85 (1): 115–22. <a href="https://doi.org/10.1152/jappl.1998.85.1.115">https://doi.org/10.1152/jappl.1998.85.1.115</a>.
</div>
<div id="ref-mourtzakis997" class="csl-entry" role="doc-biblioentry">
Mourtzakis, Marina, Carla M. M. Prado, Jessica R. Lieffers, Tony Reiman, Linda J. McCargar, and Vickie E. Baracos. 2008. <span>“A Practical and Precise Approach to Quantification of Body Composition in Cancer Patients Using Computed Tomography Images Acquired During Routine Care.”</span> <em>Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition Et Metabolisme</em> 33 (5): 997–1006. <a href="https://doi.org/10.1139/H08-075">https://doi.org/10.1139/H08-075</a>.
</div>
<div id="ref-prado269" class="csl-entry" role="doc-biblioentry">
Prado, Carla M. M., Laura A. Birdsell, and Vickie E. Baracos. 2009. <span>“The Emerging Role of Computerized Tomography in Assessing Cancer Cachexia.”</span> <em>Current Opinion in Supportive and Palliative Care</em> 3 (4): 269–75. <a href="https://doi.org/10.1097/SPC.0b013e328331124a">https://doi.org/10.1097/SPC.0b013e328331124a</a>.
</div>
<div id="ref-prado1012" class="csl-entry" role="doc-biblioentry">
Prado, Carla M., Michael B. Sawyer, Sunita Ghosh, Jessica R. Lieffers, Nina Esfandiari, Sami Antoun, and Vickie E. Baracos. 2013. <span>“Central Tenet of Cancer Cachexia Therapy: Do Patients with Advanced Cancer Have Exploitable Anabolic Potential?”</span> <em>The American Journal of Clinical Nutrition</em> 98 (4): 1012–19. <a href="https://doi.org/10.3945/ajcn.113.060228">https://doi.org/10.3945/ajcn.113.060228</a>.
</div>
<div id="ref-shen2333" class="csl-entry" role="doc-biblioentry">
Shen, Wei, Mark Punyanitya, ZiMian Wang, Dympna Gallagher, Marie-Pierre St-Onge, Jeanine Albu, Steven B. Heymsfield, and Stanley Heshka. 2004. <span>“Total Body Skeletal Muscle and Adipose Tissue Volumes: Estimation from a Single Abdominal Cross-Sectional Image.”</span> <em>Journal of Applied Physiology (Bethesda, Md.: 1985)</em> 97 (6): 2333–38. <a href="https://doi.org/10.1152/japplphysiol.00744.2004">https://doi.org/10.1152/japplphysiol.00744.2004</a>.
</div>
<div id="ref-xiao615" class="csl-entry" role="doc-biblioentry">
Xiao, Jingjie, Bette J. Caan, Elizabeth M. Cespedes Feliciano, Jeffrey A. Meyerhardt, Candyce H. Kroenke, Vickie E. Baracos, Erin Weltzien, et al. 2019. <span>“The Association of Medical and Demographic Characteristics with Sarcopenia and Low Muscle Radiodensity in Patients with Nonmetastatic Colorectal Cancer.”</span> <em>The American Journal of Clinical Nutrition</em> 109 (3): 615–25. <a href="https://doi.org/10.1093/ajcn/nqy328">https://doi.org/10.1093/ajcn/nqy328</a>.
</div>
</div></section></div></main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    target: function(trigger) {
      return trigger.previousElementSibling;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>